Decreased Mortality in Coronavirus Disease 2019 Patients Treated With Tocilizumab: A Rapid Systematic Review and Meta-analysis of Observational Studies.

Jishnu MalgieJan W SchoonesBart G Pijls

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)

Our results showed that mortality was 12% lower for COVID-19 patients treated with TCZ compared with those not treated with TCZ. The number needed to treat was 11, suggesting that for every 11 (severe) COVID-19 patients treated with TCZ, 1 death is prevented. These results require confirmation by randomized controlled trials.

Keyphrases

coronavirus disease
cardiovascular events
sars cov
randomized controlled trial
respiratory syndrome coronavirus
rheumatoid arthritis
risk factors
early onset
cardiovascular disease
rheumatoid arthritis patients
coronary artery disease
juvenile idiopathic arthritis
clinical trial
meta analyses